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Patient Characteristics n, (%)
Age, median (range), years 38(26-73)
Patients 55 years or older 23 Patients (60%)
Gender 18 Female, 20 Male
Diagnosis
AML/MDS 34/4
HLA
Match 10/10 36 patients (95%)
Match 9/10 2 Patients (5%)
Conditioning Regimen
Bu4Flu (FIC) 21 (55%)
Bu2Flu (RIC) 17 (45%)
Status at transplant
CR1 26 (68%)
CR2 3 (8%)
PIF 9 (24%)
CIBMTR risk
Low 28 (74%)
Intermediate 2(5%)
High 8(21%)
Cytogenetic risk
Low 24 (63%)
High 14 (37%)
CR¼complete remission, PIF¼ primary refractory
Table 1
Group Variables.
Variables Thiotepa (10) No Thiotepa (40) P-value
Median Range Median Range
Age (yr) 1.1 0.3- 15.5 0.9 0.1- 17.4 0.79
Infused TNC/kg8 1.21 0.37- 3.18 0.85 0.05- 4.27 0.52
Infused MNC/kg8 1.06 0.31- 2.83 0.73 0.04- 3.84 0.49
Infused CD34/kg6 0.83 0.10- 8.7 0.99 0.02- 7.6 0.31
N[ Percent N[ Percent
HLA Match 3/6, 4/6,
5/6, 6/6
0, 5,
5, 0
0, 50, 50, 0 3, 22,
8,7
8, 55, 20, 17 0.20
TBI 4 40 11 27.5 0.46
Table 2
Group Outcomes.
Outcomes Thiotepa (10) No Thiotepa
(40)
P-value
N¼ % N¼ %
Alive 9 90 21 52.5 0.037
TRM 0 0 13 32.5 0.045
Non-Engraft 1 10 13 32.5 0.07
Transplant Event 2 20 24 60 0.035
ANC Engraft 9 90 22 55 0.07
PLT Engraft 9 90 19 47.5 0.029
Chimerism >95% 9 90 17 42.5 0.006
EFS >5 yr 9 90 16 40 0.038
OS >5 yr 10 100 15 37.5 0.039
Ac GVHD 4 40 8 20 0.23
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cipients and Tacrolimus/Mycophenolate in RIC recipients.
Additionally, all the patients received thymoglobulin 1.5 mg/
Kg on day -3, -2 and -1. All patients received peripheral stem
cells except one patient with mismatch MD who received
bone marrow product.
Results: Patient Characteristics are shown in Table 1. All the
patient engrafted except one who received marrow product.
All the patients but 3 (8%) achieved 90% or more donor
chimerism by day 100. With Mean follow up of 500 days
(range, 100-1242) the overall survival (OS) was 77%  7 (CI
63-91%) at 1 year and 67%  9 (CI 49-85%) at 2 years. Simi-
larly, disease free survival was 66% 8 (CI 50-82%) at 1 and 2
years. Cumulative incidence of acute GVHD grade II-IV was
55% with grade III-IV 12%. Cumulative incidence of chronic
GVHD at 1 year was 43%with extensive chronic GVHD in 17%.
The regimen was associated with low treatment related
mortality (TRM) with cumulative incidence of only 5% at one
year, CI 14-21%. The cumulative incidence of relapse at one
year was 29%, CI 17-49%. On univariate analysis only high risk
CIBMTR status was predictive of poor OS (p¼0.05).
Conclusion: The addition of low dose thymoglobulin to RIC
and FIC regimens with iv Busulfan/Fludarabine prior to MUD
HCT results in low TRM and improved OS for patients with
AML/MDS. Relapse rate does not seem to be increased in this
cohort by the addition of low dose thymoglobulin in com-
parison to historical control.
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We retrospectively evaluated all CBT performed for non-
malignant conditions to determine if there is any correlation
between transplant outcomes & conditioning, including Total
body irradiation, Fludarabine, Cyclophosphamide, Etoposide
& Thiotepa.
Between 1/1995 & 1/2011, 50 CBT were performed. Condi-
tioning: TBI + VP16 + Cy (11); TBI + TT  VP16 + Cy (4); TT +
FLUD  Bu  VP16 (6); Bu + Cy (11); Bu + FLUD (15); VP + Cy
(2); no conditioning (1). Diagnoses: Immunodeﬁciency (22),
BM failure (10), Metabolic disease (6), Histiocytic disease (6),
Hemoglobinopathy (6).
There were 20 F, 30 M. Median age 1.0 yr (0.1 e17.4), wt 9.15
kg (3.0 - 52.0). HLA match: 6/6 (7), 5/6 (13), 4/6 (27), 3/6 (3).
Median cell dose/Kg: TNC 0.89
ˇ
8, MNC 0.77
ˇ
8, CD34 0.99
ˇ
6.
CBU were processed per Rubenstein et al. GvHD prophylaxis:
MTX + ATG + CSA (18); MMF + ATG + CSA (13); no MTX/MMF
(19); PRED or FK506 (10).
Statistical analysesweredoneusing Fisher’s Exact, Log-Rank,&
Column stats. Signiﬁcance was determined at p-value of 0.05.
Overall Results: 62% achieved ANC >500 cells/mL at 20 days
(11 - 40); 56% had PLT >20,000 at 40 d (14 - 100); & 52%
achieved>95% chimerism at 43 d (13 - 169). 13 pts died from
day + 100 TRM. 30pts are survivors at this time. EFS> 1, 3, 5 yr
was 44, 32 & 30%, with OS of 62, 46 & 42%. 8 pts are event free
>10 yr. Median follow up was 2.0 yr (0.2- 14.6 yr). Acute
GVHDgrade II - IVwas seen in 12, therewas no chronic GVHD.
Conclusion: In this cohort patients who received Thiotepa in
addition to other conditioning showed statistically signiﬁ-
cant transplant outcomes. There was no TRM. 5 yr OS was
100%, EFS 90%. Thiotepa recipients had better and rapid
Figure. K-M.
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signiﬁcant. No other statistical signiﬁcance was seen be-
tween the two groups with respect to age, HLA match, cell
dose, aGVHD, or TBI or other conditioning. In conclusion,
addition of Thiotepa to conditioning regimen dramatically
changes transplant outcomes of pediatric non malignancy
patients undergoing cord blood transplantation.362
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Group Variables.
Variable African American (31)
Median Range
Age 4.0 0.2- 20.6
TNC/Kg8 0.54 0.05- 2.75
MNC/Kg8 0.44 0.04- 2.55
CD34/Kg6 0.60 0.02- 7.6
N[ %
HLA 3/6, 4/6, 5/6, 6/6 4, 19, 6, 2 13, 61, 19, 7
Malignancy: Non-Malignancy 21, 10 67.7, 32.3
TBI: No TBI 24, 7 77.4, 22.6We retrospectively evaluated all CBT to see if there is a cor-
relation between patient ethnicity & transplant outcomes.
Between 1/1995 & 1/2011 we performed 145 CBT for the
treatment of malignant (95), non-malignant (50) conditions.
Conditioning regimen: TBI + VP16 + Cy (79); TBI + TT + VP16 +
Cy (16); Bu  Cy  FLUD (31); Cy  TT or VP16 (12); other
combinations (20).
Malignancies: ALL (47), AML (29), other (19); Pt status: PR
(7), CR1 (39), CR2 (42), CR3 (7).
Non-malignancies: Immunodeﬁciency (22); BM failure (10);
Metabolic (6); Histiocytic (6); Hemoglobinopathy (6).
Cohort was 65 F, 80 M; median age 3.8 yr (0.1 - 20.6), wt 15.5
kg (3.0 - 73.0).
Ethnicity: Caucasian (52), Hispanic (44), African American
(31), Asian (13), Mid Eastern (5).
HLA match: 6/6 (15), 5/6 (38), 4/6 (83), 3/6 (9).
Median cell dose/Kg: 0.64
ˇ
8 TNC, 0.56
ˇ
8 MNC & 0.70
ˇ
6 CD34.
GvHD prophylaxis: MTX + ATG + CSA/FK506  PRED (92);
MMF + ATG + CSA (16); CSA/FK506 + ATG  PRED (37).
Statistical analyses were done using Fisher’s Exact and log-
rank tests, column stats, and T- test. Signiﬁcance was deter-
mined at p-value of 0.05.
Overall Outcomes: ANC>500 cells/mL was achieved in 70.3%
of pts at 23 days (1 - 60); 66.2% achieved PLT count of
>20,000 at 42 days (14 - 100); and 64.8% achieved >95%All Others (114) P-value
Median Range
3.6 0.1- 17.4 0.11
0.68 0.12- 4.27 0.19
0.57 0.08- 3.84 0.23
0.80 0.02- 8.7 0.80
N[ %
5, 64, 32, 13 4, 56, 28, 11 0.18
74, 40 64.9, 35.1 0.83
71, 43 62.3, 37.7 0.14
